Rhythm Pharmaceuticals, Inc. cash flow to debt ratio of -2.90K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Rhythm Pharmaceuticals, Inc.'s free cash flow has decreased 2.41% from $-113.88M last year to $-116.63M, signaling decreasing performance

Rhythm Pharmaceuticals, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Rhythm Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.02 today, signaling strengthened financials

Rhythm Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Rhythm Pharmaceuticals, Inc.'s interest coverage ratio is -10.86, which means that the company struggles to meet interest obligations, signaling financial risk.

Rhythm Pharmaceuticals, Inc.'s profit margin has increased (-57.26%) in the last year from -200.27% to -85.59%, signaling increasing performance

Rhythm Pharmaceuticals, Inc.'s short-term assets of $466.92M exceed its short-term liabilities of $105.94M

Rhythm Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rhythm Pharmaceuticals, Inc.'s return on equity of -80.48%, is lower than 15.00%, indicating bad performance

Rhythm Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rhythm Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Rhythm Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Rhythm Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Rhythm Pharmaceuticals, Inc.'s yearly earnings has increased -24.58% since last year from $-260.60M to $-196.54M, signaling increasing performance

Rhythm Pharmaceuticals, Inc.'s yearly revenue has increased 45.83% since last year from $130.13M to $189.76M, signaling increasing performance

ROIC -63.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rhythm Pharmaceuticals, Inc.'s 3-year revenue CAGR of 100.23% is positive, indicating growing revenue over the past 3 years

Rhythm Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Rhythm Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Rhythm Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rhythm Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rhythm Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rhythm Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rhythm Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rhythm Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rhythm Pharmaceuticals, Inc. has a price-to-book ratio of 36.45x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Rhythm Pharmaceuticals, Inc. has a price-to-sales ratio of 33.02x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue